0000950170-24-025900.txt : 20240305
0000950170-24-025900.hdr.sgml : 20240305
20240305161012
ACCESSION NUMBER: 0000950170-24-025900
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEONARD JOHN M
CENTRAL INDEX KEY: 0001563584
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 24720411
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS INC
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: LEONARD JOHN M.
DATE OF NAME CHANGE: 20121204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-03-01
0001652130
Intellia Therapeutics, Inc.
NTLA
0001563584
LEONARD JOHN M
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
true
true
false
false
President and CEO
false
Common Stock
2024-03-01
4
A
false
113586
0
A
960072
D
Common Stock
58415
I
By Trust
Stock Option (right to buy)
32.66
2024-03-01
4
A
false
163929
0
A
2034-02-28
Common Stock
163929
163929
D
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
James Basta, attorney-in-fact
2024-03-05